Roche vs Cipla: A Patent Disappointment?
Given that the recent Roche vs Cipla decision was effectively India’s first post trial pharma patent ruling in a post TRIPS world, one might be forgiven for expecting a lot. Sadly, it disappointed…on several fronts. As I’d noted in an earlier post, the ruling suffers from serious jurisprudential flaws, with the Delhi High court effectively conflating issues of validity and infringement. A Mint article by CH Unnikrishnan encapsulates my views as below: “While many of us are happy about the […]
Roche vs Cipla: A Patent Disappointment? Read More »








